Factors affecting engraftment of allogeneic hematopoietic stem cells after reduced-intensity conditioning

References

• Truitt RL, Atasoylu AA. Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft versus leukemia reactivity, and tolerance after bone marrow transplantation. Blood 1991;77:2515— 23.
   PubMed Web of Science ®Google Scholar
• Sykes M, Sharabi Y, Scahs DH. Achieving alloengraftment without graft-versus-host disease: approaches using mixed allogeneic bone marrow transplantation. Bone Marrow Transplant 1998;3:379— 86.
   Google Scholar
• Vallera DA, Taylor PA, Sprent J, Blazar BR. The role of host Tcell subsets in bone marrow rejection directed to isolated major histocompatibility complex class I versus class II differences of bm1 and bm12 mutant mice. Transplantation 1994;57:249— 56.
   PubMed Web of Science ®Google Scholar
• Bachar-Lustig E, Rachamim N, Li HW et al. Megadose of T celldepleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat Med 1995;1:1268— 73.
   PubMed Web of Science ®Google Scholar
• Hiruma K, Hirsh R, Patchen M et al. Effects of anti-CD3 monoclonal antibody on engraftment of T cell depleted bone marrow allografts in mice: host T-cell suppression, growth factors, and space. Blood 1992;79:3050–8.
   PubMed Web of Science ®Google Scholar
• Kaufman CL, Colson YL, Wren SM et al. Phenotypic char-acterization of a novel bone marrow derived cell that facilitates engraftment of allogeneic bone marrow stem cells. Blood 1994;84:2436–46.
   PubMed Web of Science ®Google Scholar
• Uharek L, Gassmann W, Glass B et al. Influence of cell dose andgraft-versus host reactivity on rejection rates after allogeneic bone marrow transplantation. Blood 1992;79:1612— 21.
   PubMed Web of Science ®Google Scholar
• Gale RP, Reisner Y. Graft rejection and graft-versus-host disease: mirror images. Lancet 1986;1:1468— 70.
   PubMed Web of Science ®Google Scholar
• Champlin RE. T-cell depletion for bone marrow transplantation: effects on graft rejection, graft-versus-host disease, graft versus leukemia, and survival. Cancer Treat Res 1990;50:99–111.
   PubMedGoogle Scholar
• Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia with myeloa-blative therapy. Blood 1997;89:4531— 6.
   PubMed Web of Science ®Google Scholar
• Slavin S, Nagler A, Naparstek E et al. Non myeloablative stemcell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytor-eduction for the treatment of malignant and non-malignant hematologic diseases. Blood 1998;91:756–63.
   PubMed Web of Science ®Google Scholar
• Childs R, Clave E, Contentin N et al. Engraftment kinetics afternonmyeloablative allogeneic peripheral blood stem cell trans-plantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999;94:3234–41.
   PubMed Web of Science ®Google Scholar
• Chakraverty R, Peggs K, Chopra R et al. Limiting transplanta-tion-related mortality following unrelated donor stem cell transplantation by using a non-myeloablative conditioning regi-men. Blood 2002;99:1071–8.
   PubMed Web of Science ®Google Scholar
• Mc Sweeney PA, Niederwieser D, Shizuru JA et al. Hemato-poietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-rumor effects. Blood 2001;97:3390— 400.
   PubMed Web of Science ®Google Scholar
• Spitzer TR, McAfee S, Sacstein R et al. Intentional induction of mixed chimerism and achievement of anti-tumor responses after non-myeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant 2000;6:309–20.
   PubMed Web of Science ®Google Scholar
• Carvallo C, Geller N, Kurlander R et al. Prior chemotherapy andallograft CD34+ dose impact donor engraftment following non-myeloablative allogeneic stem cell transplantation in pa-tients with solid rumors. Blood 2004;103:1560— 3.
   PubMedGoogle Scholar
• Mackall CL, Fleisher TA, Brown MR et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994;84:2221— 8.
   PubMed Web of Science ®Google Scholar
• Petrus MJ, Williams JF, Eckhaus MA et al. An immunoablativeregimen of fludarabine and cyclophosphamide prevents fully MHC-mismatched murine marrow graft rejection independent of GVHD. Biol Blood Marrow Transplant 2000;6:182–9.
   PubMed Web of Science ®Google Scholar
• Bishop MR, Whit-Shan Hou J, Wilson WH et al. Establishmentof early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft- versus-lymphoma effect against refractory lymphomas. Biol Blood Marrow Transplant 2003;9:162–9.
   PubMed Web of Science ®Google Scholar
• Bishop MR, Steinberg SM, Gress RE et al. Targeted pretrans-plant host lymphocyte depletion prior to T-cell depleted reduced-intensity allogeneic stem cell transplantation. Br Haematol 2004;126(6):837–43.
   PubMed Web of Science ®Google Scholar
• Craddock C, Bardy P, Kreiter S et al. Engraftment of T-cell depleted allogeneic haematopoietic stem cells using a reduced intensity-conditioning regimen. Br Haematol 2000;111:797— 800.
   PubMed Web of Science ®Google Scholar
• Kreiter S, Winkelmann N, Schneider PM et al. Failure of sustained engraftment after non-myeloablative conditioning with low-dose TB! and T cell reduced allogeneic peripheral stem cell transplantation. Bone Marrow Transplant 2001;28: 157–61.
   PubMed Web of Science ®Google Scholar
• Passweg JR, Meyer-Monard S, Gregor M et al. High stem celldose will not compensate for T cell depletion in allogeneic non-myeloablative stem cell transplantation. Bone Marrow Transplant 2002;30:267— 71.
   PubMed Web of Science ®Google Scholar